ASCO: Novel targeted cancer therapies demonstrate activity and...
ABSTRACTS: 3000 and 3005
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual...
ASCO: Novel CAR T therapy and shorter targeted therapy...
ABSTRACTS: 6504, 6507
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from...
ASCO: MD Anderson’s Sharon Giordano and Richard Gorlick...
In honor of their outstanding contributions to the field of oncology, two researchers from The University of MD Anderson Cancer Center...
MD Anderson Research Highlights: ASCO 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
MD Anderson Research Highlights for May 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
End-of-life systemic treatment for patients with advanced...
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy,...
MD Anderson Research Highlights for May 8, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
Increasing doses of varenicline or nicotine replacement...
For most smokers, quitting on the first attempt is likely to be unsuccessful, but a new study from The University of Texas MD Anderson...
MD Anderson researcher Sharon Dent elected to prestigious...
Sharon Dent, Ph.D., professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has...
MD Anderson and Pan American Health Organization join...
The University of Texas MD Anderson Cancer Center and the Pan American Health Organization (PAHO) today announced the signing of an...